“We use cookies on this website to enhance your user experience and to personalise content. By clicking any link or continuing to use our Website you agree to our cookies as per our Privacy Policy. Read More” Ok, I agree

Lasmiditan (Reyvow)

Trade Name : Reyvow

Eli Lilly and Company

TABLET

Strength 50 mg/1

LASMIDITAN

Delivery Process

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

We’ll Get in Touch

Once we review your request, we’ll send you an estimated price for the medicine within 2-5 days.

Confirmation and Payment

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Product information is meant for

Wholesalers Suppliers Exporters Doctors MOH Tender Supplies Hospitals Brand CROs Comparator Supplies Generic Cooperate Sourcing Individual Patients Indian Institutional Buyers

Disclaimer

Trade Marks displayed in compliance with provisions of: Trademark Act, 1999 u/s 30 and 30 (1) of "Fair use"

GNH India is WHO GDP and ISO 9001 2015 Certified Pharmaceutical Wholesaler/ Supplier/ Exporters/ Importer from India of Lasmiditan (Reyvow) which is also known as Reyvow and Manufactured by Eli Lilly and Company. It is available in strength of 50 mg/1 per ml. Read more

Lasmiditan (Reyvow) is supplied for Tenders/ Emergency imports/ Un - licensed, Specials, Orphan drug/ Name patient line/ RLD supplies/ Reference listed drugs/ Comparator Drug/ Bio-Similar/ Innovator samples For Clinical trials.  Click to know price.     Read less

Packaging and Delivery

Validated Cold Chain Shipment

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Inquire directly from our website and get 5% off on any medicine!

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Read more

About GNH

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Read more
  • No data
  • REYVOWu2122 is indicated for the acute treatment of migraine with or without aura in adults.n
  • Limitations of Use
  • REYVOW is not indicated for the preventive treatment of migraine.n
  • REYVOWu2122 is a serotonin (5-HT) 1F receptor agonist indicated for the acute treatment of migraine with or without aura in adults. ()n
  • Limitations of Use
  • REYVOW is not indicated for the preventive treatment of migraine. ()n
  • The recommended dose of REYVOW is 50u00a0mg, 100u00a0mg, or 200u00a0mg taken orally, as needed. No more than one dose should be taken in 24u00a0hours, and REYVOW should not be taken unless the patient can wait at least 8u00a0hours between dosing and driving or operating machinery .n
  • A second dose of REYVOW has not been shown to be effective for the same migraine attack.n
  • The safety of treating an average of more than 4 migraine attacks in a 30-day period has not been established.n
  • REYVOW may be taken with or without food.n
  • The recommended dose is 50u00a0mg, 100u00a0mg, or 200u00a0mg taken orally, as needed. ()n
  • No more than one dose should be taken in 24u00a0hours. (, )n
  • REYVOW (lasmiditan) tablets are available in two strengths:n
  • Tablets: 50u00a0mg, 100u00a0mg ()n
  • None.n
  • None. ()n
  • No data
  • Driving Impairment: Advise patients not to drive or operate machinery until at least 8u00a0hours after taking each dose of REYVOW. Patients who cannot follow this advice should not take REYVOW. Patients may not be able to assess their own driving competence and the degree of impairment caused by REYVOW. ()n
  • Central Nervous System (CNS) Depression: REYVOW may cause CNS depression and should be used with caution if used in combination with alcohol or other CNS depressants. (, )n
  • Serotonin Syndrome: Reactions consistent with serotonin syndrome were reported in patients treated with REYVOW. Discontinue REYVOW if symptoms of serotonin syndrome occur. ()n
  • Medication Overuse Headache: Detoxification may be necessary. ()n
  • The following clinically significant adverse reactions are described elsewhere in the labeling:n
  • Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.n
  • The safety of REYVOW has been evaluated in 4,878 subjects who received at least one dose of REYVOW. In 2 placebo-controlled, Phase 3 trials in adult patients with migraine (Studies 1 and 2), a total of 3,177 patients received REYVOW 50, 100, or 200u00a0mg . Of the REYVOW-treated patients in these 2 studies, approximately 84% were female, 78% were White, 18% were Black, and 18% were of Hispanic or Latino ethnicity. The mean age at study entry was 42.4u00a0years (range 18 to 81).n
  • Long-term safety was assessed for 2,030 patients, dosing intermittently for up to 12u00a0months in a long-term safety study. Of these, 728 patients were exposed to 100u00a0mg or 200u00a0mg for at least 3u00a0months, 361 patients were exposed to these doses for at least 6u00a0months, and 180 patients were exposed to these doses for at least 12u00a0months, all of whom treated at least 2 migraine attacks per month on average. In that study, 14% (148 out of 1,039) in the 200u00a0mg dose group, and 11% (112 out of 991) in the 100u00a0mg dose group withdrew from the trial because of an adverse event. The most common adverse event resulting in discontinuation in the long-term safety study (greater than 2%) was dizziness.n
  • Most common adverse reactions (u22655% and > placebo) were dizziness, fatigue, paresthesia, and sedation. ()n
  • To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
  • No data
  • REYVOW may further lower heart rate when administered with heart rate lowering drugs. ()n
  • Avoid concomitant use with P-gp and Breast Cancer Resistant Protein (BCRP) substrates. ()n
  • No data
  • Based on animal data, may cause fetal harm. ()n
  • REYVOW has not been studied in patients with severe hepatic impairment (Child-Pugh C) and its use in these patients is not recommended. ()n
  • No data
  • REYVOW (lasmiditan) is a serotonin (5-HT) 1F receptor agonist for oral administration. The chemical name of lasmiditan hemisuccinate is 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)pyridine-2-yl]benzamide hemisuccinate. It has the empirical formula of CHFNOu20220.5[CHO] and a molecular weight of 436.41 (hemisuccinate). Lasmiditan hemisuccinate has the following structural formula:n
  • Lasmiditan hemisuccinate is a white, crystalline powder that is sparingly soluble in water, slightly soluble in ethanol, and soluble in methanol. A 1u00a0mg/mL aqueous solution of lasmiditan hemisuccinate has a pH of 6.8 at ambient conditions.n
  • REYVOW 50u00a0mg tablets contain 50u00a0mg lasmiditan (equivalent to 57.824u00a0mg lasmiditan hemisuccinate) and the inactive ingredients as follows:n
  • Excipients u2013 croscarmellose sodium, magnesium stearate, microcrystalline cellulose, pregelatinized starch, sodium lauryl sulfate.n
  • Color mixture ingredients u2013 black ferric oxide, polyethylene glycol, polyvinyl alcohol, talc, titanium dioxide.n
  • REYVOW 100u00a0mg tablets contain 100u00a0mg lasmiditan (equivalent to 115.65u00a0mg lasmiditan hemisuccinate) and the inactive ingredients as follows:n
  • Excipients u2013 croscarmellose sodium, magnesium stearate, microcrystalline cellulose, pregelatinized starch, sodium lauryl sulfate.n
  • Color mixture ingredients u2013 black ferric oxide, polyethylene glycol, polyvinyl alcohol, red ferric oxide, talc, titanium dioxide.n
  • No data
  • No data
  • No data
  • No data
  • Advise the patient to read the FDA-approved patient labeling ().
  • REY-0001-MG-202001n
  • PACKAGE LABEL - REYVOW 50 mg 8ct carton
  • NDC 0002-4312-08ntttttt
  • 8 tablets (2 cards of 4 tablets)ntttttt
  • REYVOWu2122n
  • (lasmiditan) CVn
  • tablets 50 mgn
  • Each tablet contains 50 mg of lasmiditan.n
  • Rx onlyntttttt
  • www.REYVOW.comn
  • 50 mgn
  • Dispense enclosed Medication Guide to each patient.n
  • Lillyn
  • PACKAGE LABEL - REYVOW 100 mg 8ct carton
  • NDC 0002-4491-08ntttttt
  • 8 tablets (2 cards of 4 tablets)ntttttt
  • REYVOWu2122n
  • (lasmiditan) CVn
  • tablets 100 mgn
  • Each tablet contains 100 mg of lasmiditan.n
  • Rx onlyntttttt
  • www.REYVOW.comn
  • 100 mgn
  • Dispense enclosed Medication Guide to each patient.n
  • Lillyn

Similar Products

Desogestrel And Ethinyl Estradiol (Emoquette)

Desogestrel And Ethinyl Estradiol (Emoquette)

Manufacturer: REMEDYREPACK INC.

Presentation: KIT

Strength:

Pack Size:

Diphenoxylate Hydrochloride And Atropine Sulfate (Diphenoxylate Hydrochloride And Atropine Sulfate)

Diphenoxylate Hydrochloride And Atropine Sulfate (Diphenoxylate Hydrochloride And Atropine Sulfate)

Manufacturer: REMEDYREPACK INC.

Presentation: TABLET

Strength: 2.5; .025 mg/1; mg/1

Pack Size:

Fluoxetine Hydrochloride (Fluoxetine)

Fluoxetine Hydrochloride (Fluoxetine)

Manufacturer: REMEDYREPACK INC.

Presentation: CAPSULE

Strength: 40 mg/1

Pack Size:

Metoprolol Succinate (Metoprolol Succinate)

Metoprolol Succinate (Metoprolol Succinate)

Manufacturer: REMEDYREPACK INC.

Presentation: TABLET, EXTENDED RELEASE

Strength: 25 mg/1

Pack Size:

Losartan Potassium (Losartan Potassium)

Losartan Potassium (Losartan Potassium)

Manufacturer: REMEDYREPACK INC.

Presentation: TABLET, FILM COATED

Strength: 25 mg/1

Pack Size:

Browse Our Services And Processes

Comparator Sourcing for Clinical Trials

Comparator Sourcing for Clinical Trials

GNH India brings over 10 years of experience in Comparator

Read More

Name Patient Supply

Name Patient Supply

Today, the exact cause for many rare diseases remains unknown

Read More

Validated Cold Chain Shipment

Validated Cold Chain Shipment

With shifting of pharma industry from synthetic molecules to biologic

Read More

Clinical Trials Supply

Clinical Trials Supply

STOP SOURCING..... START SMART SOURCING...... COME STRAIGHT TO THE SOURCE

Read More

Pharmaceutical Contract Manufacturing

Pharmaceutical Contract Manufacturing

GNH Provides Contract Manufacturing services for: Generic Medicines with following

Read More

Pricing

Pricing

PRICING POLICY Terms of sales are typically prepaid, unless otherwise

Read More

Disclaimer

Please see the Legal Notice for detailed terms and disclaimers. The Legal Notice governs the use of this Website and by accessing and using this Website you agree to be bound by and accept the Legal Notice.

Browse from other international pharmaceuticals

General

64020 Products

GNH India Brings to over 64036 Product SKUs from India all at 1 place with easy access and global deliveries.

US NDC

71246 Products

GNH India Brings to over 71252 Product SKUs from India all at 1 place with easy access and global deliveries.

Canadian DIN

51046 Products

GNH India Brings to over 51047 Product SKUs from India all at 1 place with easy access and global deliveries.

Swiss Drugs

150 Products

GNH India Brings to over 150 Product SKUs from India all at 1 place with easy access and global deliveries.

NZ Drugs

13296 Products

GNH Brings to over 13298 Product SKUs from India all at 1 place with easy access and global deliveries.

FAQ

Check out our delivery process

Can’t find what
you’re looking for?

Contact US
Get Price

Are you an existing customer or a vendor of GNH India? Log in here to

View your Transaction
COMPANY
SERVICES
QUICK LINKS
CONTACT US
Registered Office Address:

Unit # G- 14, 15, 16, 17, Ground Floor, Prabhadevi Industrial Estate, Enterprises Industrial Premises, 408, Veer Sawarkar Road, Prabhadevi,
Mumbai 400025 India

US Office Address:

GNH Pharmaceuticals USA LLC,
Suite E # 499, 1235 EAST BLVD,
Charlotte, NC, 28203, U.S.A
TEL: +1 704 557 0412

Pharmexcil
DB
FIEO-2016
SiteLock

Copyright © 2024 GNHIndia .com. All Rights Reserved. Please read Legal Notice for further details.

Disclaimer: Product names, logos, brands and other trademarks featured or referred to are the property of their respective trademark holders.